

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

Decree on the admission restriction and the admission procedure for the jointly established Master's Programme in Pharmaceutical Sciences – Drug Development and Regulatory Affairs at the Medical University of Innsbruck and the Leopold-Franzens-University of Innsbruck from the academic year of 2022/2023 onwards

Preamble

The Master's Programme in Pharmaceutical Sciences – Drug Development and Regulatory Affairs, in the following referred to as PHARM_SCI, has been set up as a joint study programme held in English at the Medical University of Innsbruck and the Leopold-Franzens-University of Innsbruck. The present decree regulates access to this study programme through the PHARM-SCI admission procedure, which is carried out exclusively by the Medical University of Innsbruck for both universities prior to admission.

The Rectorate of the Medical University of Innsbruck has issued the following decree on the admission restrictions for the PHARM-SCI master's programme, in accordance with §54e, par. 1 and §63a par. 8 of the Universities Act in the currently valid version, following a statement from the Senate:

I. Content of the decree and power to issue statutory instruments

- (1) This decree regulates the number of first-year students for the PHARM_SCI master's programme at the Medical University of Innsbruck and the Leopold-Franzens-University of Innsbruck, as well as the admission procedure prior to admission to the study programme.
- (2) The Rectorate of the Medical University of Innsbruck has to determine
 - a) the correction procedure for the admission test,
 - b) the COVID-19 protection regulations and hygiene measures for all steps of the procedure in which the applicant's personal presence is required,
 - c) the provisions for the selection of applicants in the event of "parts of the PHARM_SCI admission process being prevented by force majeure" and,
 - d) if necessary due to the COVID-19 pandemic, the postponement of the test day by means of an ordinance.

II. Scope

§ 2. The regulations on access restrictions applies to all applicants for the PHARM_SCI master's programme at the Medical University of Innsbruck and the Leopold-Franzens University of Innsbruck. Applicants are only accepted at the beginning of the respective academic year.

§ 3. The regulations for the admission procedure acc. to §§ 5 ff do not apply to:

1. students who are admitted to the PHARM_SCI master's programme at the Medical University of Innsbruck or the Leopold-Franzens-University of Innsbruck resp. and continue their study programme (§62 Universities Act) as well as
2. students who are admitted to a PHARM_SCI master's programme at a university or equivalent recognised post-secondary educational institution abroad and who are studying within the framework of an international mobility programme (e.g. ERASMUS) at the Medical University of Innsbruck or the Leopold-Franzens-University of Innsbruck.

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

III. Number of study places

§ 4. (1) The following number of places is determined in accordance with the cooperation agreement between the Medical University of Innsbruck and the Leopold-Franzens-University of Innsbruck on which the jointly established programme is based on and in accordance with §63a, par. 8 Universities Act for the PHARM-SCI master's programme at the Medical University of Innsbruck and the Leopold-Franzens-University of Innsbruck: **30**

(2) Years of experience have shown that the number of students with a fix place for the study programme drops below thirty, because some applicants don't accept the study place or drop out within the first semester. Therefore, the responsible member of the Rectorate of the Medical University of Innsbruck may increase the number of places to a maximum of 33.

IV. Admission procedure for the PHARM_SCI master's programme

§ 5. (1) The admission of applicants for the PHARM_SCI master's programme is based on the admission procedure according to §§ 6 ff.

The allocation of study places takes place within the framework of the admission procedure (PHARM_SCI) in two steps:

1. Within the scope of a special knowledge test for the PHARM_SCI master's programme (PHARM-SCI test) a ranking is made in the first step. The study applicants ranked 1 to 50
2. will be invited to a selection interview in step 2.

(2) The costs incurred by applicants in the course of the admission procedure pursuant to §§ 6 ff are not reimbursable.

(3) The following people are entitled to participate in the admission procedure ((§§ 6 ff). People who acc. to §64 par. 3 Universities Act and par. 10 in the currently valid version can at the time of the admission provide proof of

1. a degree in a subject-relevant bachelor's programme, diploma programme or a subject-relevant bachelor's degree at a university of applied sciences or another equivalent study programme at a recognised post-secondary educational institution home or abroad. In any case, a bachelor's degree or diploma degree in Pharmacy, Chemistry or Biology at the Leopold-Franzens-University of Innsbruck as well as a bachelor's degree in Molecular Medicine or a diploma degree in Human Medicine at the Medical University of Innsbruck are relevant study programmes. If equality has been established in principle and only a few examinations are missing for full equivalence, additional courses and examinations covering a maximum of 30 ECTS-Credits can be prescribed for achieving full equivalence.
2. the necessary English language skills, unless their first language is English. The knowledge of the language is demonstrated in particular by a school leaving certificate based on teaching in this language (level C1),

Internet registration

§ 6. (1) Applicants must register for the admission procedure using the online web form (PHARM_SCI-account) within the registration period from 1 March 2022 to 13 May 2022.

(2) When registering on the Internet the choice of study programme and the place of study must be specified in addition to the general personal data (surname, first name, place of residence, etc.). The data processing takes place on the basis of the legal provisions, in particular on the basis of article 6 and 9 of the EU GDPR, §3 in conjunction with §63a par. 8 Universities Act and the Educational Documentation Act.

(3) Valid internet registration is a prerequisite for taking the test. It is not possible to register online after the registration period has expired (§6 (1)) or to extend the registration period. The internet registration is only

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

possible within the specified period and only becomes valid when the cost sharing has been received in full and in time (§7).

(4) The web address for the registration will be published on the internet on the website of the Medical University of Innsbruck by the end of February of the respective year at the latest. An incomplete, untruthful or untimely registration or a registration on that does not meet the formal requirements (in par. 1 to 3) is invalid and will not be considered. Order for improvement do not have to be made.

(5) It should be noted that all information for applicants regarding the admission procedure will be provided by the Medical University of Innsbruck electronically. This also means that study applicants have to actively retrieve information from an Internet platform specifically set up for this purpose.

Moreover, in accordance with §§14 and 16, applicants are obliged to check their PHARM_SCI account regularly for receipt of electronic messages from the Medical University of Innsbruck or have it checked – at least daily during the allocation period for study places.

Co-payment

§ 7. (1) The study applicants have to contribute to the cost of the test. The amount of the contribution is €80.

(2) The cost sharing must be paid within the period from 1 March 2022 to 13 May 2022 using one of the payment options offered by the Medical University of Innsbruck as part of the Internet registration and subsequently arrive in full on the account specified by the Medical University of Innsbruck within the scope of the Internet registration process. The required information will be announced during the internet registration (§6). The applicants have the express obligation to follow the announcements on the internet platform of the Medical University of Innsbruck and to pay the co-payment in such a way that the amount arrives at the specified bank account of the Medical University of Innsbruck as well as to check the valid payment of the co-payment. The applicants also must check the display of a payment confirmation in the system

(3) An internet registration is considered withdrawn if the contribution has not been received in full on the account specified by the Medical University of Innsbruck within the specified period from 1 March 2022 to 13 May 2022. The internet registration becomes invalid and participation in the admission procedure is excluded.

(4) If applicants do not appear for the test or the selection interview despite valid internet registration (§6 par. 4) and payment of the co-payment (§7 par. 2), or if they cancel, there is no entitlement to a reimbursement of the co-payment made.

Information on the selection process

§ 8. (1) Applicants who have validly registered via the internet receive an access to download information on the knowledge test and its procedure via their PHARM_SCI-account.

(2) The knowledge test will take place on 8 July 2022 and therefore on the same day as the other admission procedures at the Medical University of Innsbruck. The test location, the time and the duration of the test will be communicated to all applicants who have been validly registered through internet application (§6) and have subsequently paid the co-payment (§7) via the PHARM-SCI-account, in good time, but no later than three weeks before the test date.

(3) Applicants who are ranked 1 to 50 after the knowledge test will be invited to a selection interview. The interviews take place in the week following the admission test. Applicants will be informed of the dates via the PHARM_SCI-account.

(4) Applicants with a disability acc. to §3 BGStG who have properly registered for the admission procedure and have paid the co-payment in good time and in full, have the right to request a different examination method if the applicant can prove a disability, which makes it impossible to take an examination within the scope of the

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

admission and selection procedure using the specified method. However, the educational goal of the chosen study programme must remain attainable.

The deviating examination method may only be approved in a way that does not represent any disadvantage for the other applicants taking part in the admission or selection process. A disability in terms of §3 BGStG is the affection of a not only temporal physical, mental or psychological impairment of functions or impairment of sensory functions, which makes participation in social life more difficult. A period is deemed to be non-temporary if it presumably exceeds six months.

An application for a different examination method must be submitted to anv-nachteilsausgleich@i-med.ac.at between 16 May 2022 to 27 May 2022 at the latest and evidenced by a medical certificate or expert opinion, which must be attached to the application. The disability and the necessary alternative examination method must be evident from the application and the evidence presented. Applicants who have submitted an application in due time and have provided evidence of a disability will be informed on their PHARM_SCI account after the deadline for submitting an application until June 30, 2022, whether and in what way a different examination method and, if applicable, suitable support measures are granted. Further information is published on the website (<https://www.i-med.ac.at/studium/anv-barrierefrei.html>). Applicants are obliged to regularly check the website for information and to regularly check their PHARM_SCI account for receipt of electronic messages from the Medical University of Innsbruck. Objections and legal remedies against the decision made are not permitted.

A late application is only permitted in justified exceptional cases. Orders for improvement do not have to be made.

Test execution

§ 9. (1) The allocation of study places (§ 4) for the PHARM_SCI master's programme is carried out by the PHARM_SCI admission procedure (§5 par. 1).

(2) The admission test is held in person as a computer test or, alternatively, in writing on paper. Knowledge in the fields of genetics, physiology / pathophysiology, biology / molecular biology, chemistry / biochemistry, pharmaceutical technology and biotechnology, pharmacology and statistics is checked.

(3) More information on the preparation for the test is published on the website (https://www.i-med.ac.at/studium/zulassung/erstzulassung/zulassung_pharm_sci_EN.html).

§ 10. The admission test is not an examination in the sense of §§ 72 ff. Universities Act. Therefore, the provisions of §§72 to 79 Universities Act do not apply.

§ 11. It is prohibited to pass on the test items to third parties and to exploit them. This is the exclusive right of the holder of the rights for the admission test. If this provision is violated, the Medical University of Innsbruck is entitled to indemnify and hold itself harmless.

Exclusion

§ 12. (1) Student applicants are required to independently and responsibly inform themselves of any COVID-19 pandemic-related restrictions on participation in the admissions test.

(2) Before the start of the admission procedure, the identity of the applicants must be established. For this purpose, applicants must present a valid official photo ID. If an applicant refuses to identify himself/herself or if it is not possible to establish the identity of an applicant or if there are justified doubts about the identity of an applicant, the head of the PHARM_SCI admission procedure is authorised to deny the applicant access to the test location.

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

(3) Applicants who arrive too late may be refused participation in the admission procedure by the PHARM_SCI admission procedure manager.

(4) The test supervisor has the authority to establish the seating order and to assign seats to the applicants. If an applicant does not follow the instructions of the test supervisor despite being requested to do so, the PHARM_SCI admission procedure manager is authorised to exclude the applicant in question from the admission test.

(5) If an applicant abandons the admission test, the test will not be considered in the admission procedure.

(6) Participants in the admission test who interfere with the proper conduct of the test may be excluded from further participation in the test. In this case, the entrance test will be evaluated with zero points.

(7) Participants in the entrance test who do not adhere to the COVID-19 protection regulations and hygiene measures of the Medical University of Innsbruck (§ 1 par. 2) despite being warned, will be excluded from the test, their test result will be evaluated with zero points, they will be banned from the premises and immediately expelled from the test area.

(8) Items not allowed during the test will be announced to the applicants via the PHARM_SCI account of the Medical University of Innsbruck. Participants who are still carrying unauthorised items after the start of the test will be asked to hand them in to the supervisory staff and will receive a warning. Attempts to communicate with other participants during the test will also be punished with a warning. Participants in the entrance test who have received two warnings will be excluded from further participation in the test. In this case, the admission test will be evaluated with zero points.

(9) Participants in the admission test who attempt to influence the test result by dishonesty may be excluded from further participation in the test.

Dishonesty occurs in particular if, after the start of the test, participants use an unauthorised item that was communicated in advance by the PHARM_SCI account of the Medical University of Innsbruck without permission. If participants in the entrance test are excluded from further participation in the test due to dishonesty, or if dishonesty is detected after completion of the entrance test, the entrance test will be evaluated with zero points.

(10) The incidents mentioned in paragraphs 2 to 9 as well as other extraordinary incidents are to be documented by the test supervisor in an appropriate manner.

(11) Applicants who have been eliminated by the responsible admission procedure director will be escorted out of the test area and the admission test will be evaluated with zero points.

Evaluation and Selection

§ 13. (1) The knowledge test is evaluated by the Medical University of Innsbruck. The result of the knowledge test and the resulting ranking determines who will be invited to a selection interview. The ranking will be published on the internet platform.

(2) If parts of the PHARM_SCI admission procedure are prevented by force majeure, the selection of applicants shall be made in accordance with the regulation "Prevention of parts of the PHARM_SCI admission procedure by force majeure".

Determination of results, ranking list and allocation of study places

§ 14. (1) Applicants who are placed in positions 1 to 50 in the ranking based on the knowledge test are given the opportunity to participate in a selection interview. There is a selection committee appointed by the responsible members of the rectorates of both universities, which draws up a list of questions that is binding for all.

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

(2) The results from the entrance test and the selection interview decide on the allocation of a study place. The results of these selection interviews lead to the final ranking list for the allocation of a study place. The applicants in positions 1 to 30 of the final ranking or the positions corresponding to the number of study places as specified in §4 par. 2, shall be allocated a study place.

(3) If more than one applicant achieves the same rank at the last rank (rank binding), the study place will be awarded by a lottery procedure.

(4) If an applicant does not appear for the selection interview, the place on the list obtained is forfeited. The selection interview is not an examination in the sense of §§72 ff. Universities Act. The provisions of §§72 to 79 Universities Act shall not apply.

COVID-19 Pandemic

§ 15. (1) Applicants are obliged to inform themselves independently and on their own responsibility about all pandemic-related restrictions on participation in testing and all other procedural steps that require personal presence.

(2) Applicants who, due to their belonging to a COVID 19 risk group, require special protection when taking the test, must inform the university by 17 June 2022 by sending an e-mail to anv-nachteilsausgleich@i-med.ac.at, enclosing a COVID 19 risk attestation in accordance with the COVID 19 Risk Group Ordinance (BGBl. II No. 203/2020).

(3) Applicants who do not comply with the COVID-19 protection regulations and hygiene measures of the Medical University of Innsbruck for the conduct of the admission procedure for the respective academic year, despite having been warned, will not be allowed to enter the test rooms or premises of the university. If the violation occurs on the test premises, they will be excluded from the test, their test result will be assessed with zero points, they will be banned from the premises and immediately expelled from the test area. The COVID-19 protection regulations and hygiene measures of the Medical University of Innsbruck for the implementation of the admission procedure for the respective academic year are published on the website <https://www.i-med.ac.at/studium/covid-19-Massnahmen.html>.

V. Admission

§ 16. (1) Only those applicants who have been offered a study place for this study programme on the basis of the ranking list (§14) can be admitted to the master's programme. Admission takes place exclusively at the Leopold-Franzens-University of Innsbruck (<https://www.uibk.ac.at/studium/anmeldung-zulassung/aufnahmev-erfahren-neu>).

According to §54e par. 4 Universities Act, the applicants also become members of the Medical University of Innsbruck with their admission. The regulations concerning the responsibilities for the implementation of the provisions of study law as well as the application of the respective provisions of the study law statutes are laid down in ordinances issued in the same wording, which are published in the respective bulletins of both universities.

(2) The admission to the Master's Programme in PHARM_SCI requires that the applicant has obtained a place in the final ranking list (§14) for the relevant academic year and fulfils the requirements of §§63 ff. and 91 Universities Act.

(3) The admission of applicants who have not achieved a place on the ranking list according to § 14 is inadmissible.

(4) The obligation of the applicants, according to §6, to check their PHARM_SCI account regularly - in the times of the allocation of study places at least daily - for the receipt of electronic messages from the Medical University of Innsbruck is explicitly pointed out.

Die nachstehende, auf Englisch abrufbare Version der Aufnahmeverordnung PHARM_SCI ist rechtlich nicht verbindlich und dient lediglich zur Information.

ENGLISCH: The following version of the PHARM_SCI admission regulations in English are not legally binding and for informational purposes only.

VI. Repeated participation in the admission procedure

§ 17. Applicants who are not admitted to the programme in one academic year may participate in the admission procedure in the following academic years. Repeated participation in the admission procedure for students who are not admitted in one academic year is possible for an unlimited period. They are treated in the same way as applicants who participate in the admission procedure for the first time.

VII. Responsibility, coming-into-force

§ 18. The Rectorate of the Medical University of Innsbruck is responsible for the implementation of the admission procedure.

§ 19. This Regulation shall enter into force on the day of its publication in the official gazette of the Medical University of Innsbruck.

For the Rectorate:

ao. Univ.-Prof. Dr. med. univ. Wolfgang Prodingler, MME (Bern)
Vice Rector for Student Affairs and Teaching